114 related articles for article (PubMed ID: 8354981)
21. Evaluation of oral anticoagulant therapy by measuring plasma prothrombin fragment 1 + 2.
Takahashi H; Wada K; Satoh N; Takakuwa E; Furuta R; Yoshino N; Shibata A
Blood Coagul Fibrinolysis; 1993 Jun; 4(3):435-9. PubMed ID: 8329570
[TBL] [Abstract][Full Text] [Related]
22. Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex.
Kapiotis S; Jilma B; Quehenberger P; Ruzicka K; Handler S; Speiser W
Circulation; 1997 Jul; 96(1):19-21. PubMed ID: 9236409
[TBL] [Abstract][Full Text] [Related]
23. Critical role of factors II and X during coumarin anticoagulation and their combined measurement with a new Fiix-prothrombin time.
Gudmundsdottir BR; Francis CW; Bjornsdottir AM; Nellbring M; Onundarson PT
Thromb Res; 2012 Oct; 130(4):674-81. PubMed ID: 22225856
[TBL] [Abstract][Full Text] [Related]
24. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes.
Eikelboom JW; Weitz JI; Budaj A; Zhao F; Copland I; Maciejewski P; Johnston M; Yusuf S
Eur Heart J; 2002 Nov; 23(22):1771-9. PubMed ID: 12419297
[TBL] [Abstract][Full Text] [Related]
25. Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1 + 2 in patients with atrial fibrillation.
Koefoed BG; Feddersen C; Gulløv AL; Petersen P
Thromb Haemost; 1997 May; 77(5):845-8. PubMed ID: 9184390
[TBL] [Abstract][Full Text] [Related]
26. Predicting warfarin maintenance dosage based on initial response.
Miller DR; Brown MA
Am J Hosp Pharm; 1979 Oct; 36(10):1351-5. PubMed ID: 507078
[TBL] [Abstract][Full Text] [Related]
27. Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels.
Yamazaki H; Yagi S; Torii Y; Amano R; Oomichi Y; Sangawa T; Fukuda D; Kadota M; Ise T; Ueno R; Hara T; Kusunose K; Matsuura T; Tobiume T; Yamaguchi K; Yamada H; Soeki T; Wakatsuki T; Akaike M; Sata M
J Cardiol; 2018 Mar; 71(3):305-309. PubMed ID: 29100817
[TBL] [Abstract][Full Text] [Related]
28. Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations.
Palareti G; Legnani C
Clin Pharmacokinet; 1996 Apr; 30(4):300-13. PubMed ID: 8983860
[TBL] [Abstract][Full Text] [Related]
29. Comparison of plasma prothrombin and factor VII and urine prothrombin F1 concentrations in patients on long-term warfarin therapy and those in the initial phase.
Weinstock DM; Chang P; Aronson DL; Kessler CM
Am J Hematol; 1998 Mar; 57(3):193-9. PubMed ID: 9495368
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of factor VIIa generation and prothrombin activation by treatment with enoxaparin in patients with unstable angina.
Gerotziafas GT; Zafiropoulos A; Van Dreden P; Karavaggeli E; Goutzoumas N; Nikolaidis P; Combot C; Lagoudaki P; Zervas K; Arzoglou P; Samama MM
Br J Haematol; 2003 Feb; 120(4):611-7. PubMed ID: 12588347
[TBL] [Abstract][Full Text] [Related]
31. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
[TBL] [Abstract][Full Text] [Related]
32. Influence of vinpocetine on warfarin-induced inhibition of coagulation.
Hitzenberger G; Sommer W; Grandt R
Int J Clin Pharmacol Ther Toxicol; 1990 Aug; 28(8):323-8. PubMed ID: 2272713
[TBL] [Abstract][Full Text] [Related]
33. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation.
Tanaka KA; Szlam F; Dickneite G; Levy JH
Thromb Res; 2008; 122(1):117-23. PubMed ID: 17977586
[TBL] [Abstract][Full Text] [Related]
34. Which coagulation factors interfere with the one-stage prothrombin time?
Talstad I
Haemostasis; 1993; 23(1):19-25. PubMed ID: 8477905
[TBL] [Abstract][Full Text] [Related]
35. Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium.
Crussell-Porter LL; Rindone JP; Ford MA; Jaskar DW
Arch Intern Med; 1993 Jan; 153(1):102-4. PubMed ID: 8422191
[TBL] [Abstract][Full Text] [Related]
36. Dietary factor VII activation does not increase plasma concentrations of prothrombin fragment 1+2 in patients with stable angina pectoris and coronary atherosclerosis.
Bladbjerg EM; Münster AM; Marckmann P; Keller N; Jespersen J
Arterioscler Thromb Vasc Biol; 2000 Nov; 20(11):2494-9. PubMed ID: 11073858
[TBL] [Abstract][Full Text] [Related]
37. Coagulant activity during one year after bioprosthetic aortic valve replacement.
Imagawa H; Ryugo M; Shikata F; Nakata T; Nagashima M; Kawachi K
Interact Cardiovasc Thorac Surg; 2009 Apr; 8(4):417-20. PubMed ID: 19141491
[TBL] [Abstract][Full Text] [Related]
38. Anti-factor IXa Aptamer reduces propagation of thrombin generation in plasma anticoagulated with warfarin.
Szlam F; Luan D; Bolliger D; Szlam AD; Levy JH; Varner JD; Tanaka KA
Thromb Res; 2010 May; 125(5):432-7. PubMed ID: 20004955
[TBL] [Abstract][Full Text] [Related]
39. The effects of coumadin on the prothrombin (factor II) coagulation pathway in man: relationship between antigen and activity levels.
Lox CD; Maciulla GJ; Heine MW; Messiha FS; Corrigan JJ
Proc West Pharmacol Soc; 1978; 21():237-9. PubMed ID: 693503
[No Abstract] [Full Text] [Related]
40. Warfarin therapy. 1.
Deykin D
N Engl J Med; 1970 Sep; 283(13):691-4. PubMed ID: 4916914
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
